Roche: Genentech to present new phase III data in hemophilia
(CercleFinance.com) - Roche's Genentech plans to present new phase III data for Hemlibra in people with hemophilia A at the World Federation of Hemophilia 2018 World Congress at the end of the month, the company said.
Data includes results from a study in people with hemophilia A without factor VIII inhibitors and another study in people with hemophilia A with or without factor VIII inhibitors Genentech said.
The firm said the results demonstrate the potential that Hemlibra has to redefine treatment expectations for people with both kinds of diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Data includes results from a study in people with hemophilia A without factor VIII inhibitors and another study in people with hemophilia A with or without factor VIII inhibitors Genentech said.
The firm said the results demonstrate the potential that Hemlibra has to redefine treatment expectations for people with both kinds of diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.